An observational study in Upper Limb Injury, sponsored by Ipsen. Active, not recruiting at 27 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Ipsen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to perform, in real world clinical practice, a three-dimensional assessment from patient's, caregiver's and physician's perspectives, of the impact of AboBoNT-A on caregiver burden, functional disability and other health care measures in patients affected with ULS due to acquired brain injuries.
64 studies on the registry are indexed under Arm Injuries; 11 are open to participants now.
This study's planned enrollment of 113 is above the median of 101 across 16 observational studies indexed under Arm Injuries.
Browse Arm Injuries studies →Ipsen is the lead sponsor of 290 studies on the registry; 18 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients with ULS who will start AboBoNT-A treatment in upper limbs as part of routine clinical practice should be recruited. Patients who received BoNT-A injections in upper limbs less than one year prior to inclusion should not be included in the study. Patients who previously received BoNTA injections in body parts other than upper limbs could be included in the study, regardless of injection anteriority.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The patient is supported by an identified caregiver (family member or other nonpaid adult
- if the patient has more than one caregiver, the main caregiver will be selected) who provides daily supervision or direct assistance to the care recipient;
For Caregivers :
(8) The caregiver is able to comply with the protocol; (9) Male and female caregivers who are at least 18 years old; (10) The cognitive and health status of the caregiver is compatible with the participation to the study.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change from baseline in the 5-item Carer Burden Scale (CBS) mean score
The 5-item Carer Burden Scale is 5-point Likert scale ranging from 0 (no difficulty) to 4 (cannot complete the task), so that higher scores indicate greater burden.
Time frame: From baseline to 8 weeks
Patient's demographic data
Patient's Characteristics
Time frame: through study completion, an average of 14 months
Caregiver's demographic data;
Patient's Characteristics
Time frame: through study completion, an average of 14 months
Aetiology of spasticity;
Patient's Characteristics
Time frame: through study completion, an average of 14 months
Affected upper limb
Patient's Characteristics
Time frame: through study completion, an average of 14 months
Ascribed spastic muscle group(s);
Patient's Characteristics
Time frame: through study completion, an average of 14 months
Time since onset of the aetiology of upper limb spasticity (ULS)
Patient's Characteristics
Time frame: through study completion, an average of 14 months
Associated lower limb spasticity (LLS)
Patient's Characteristics
Time frame: through study completion, an average of 14 months
Global autonomy evaluation (modified Rankin Scale).
Patient's Characteristics
Time frame: through study completion, an average of 14 months
Total dose injected in ULS per cycle;
Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.
Time frame: through study completion, an average of 14 months
Dose per muscle group;
Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.
Time frame: through study completion, an average of 14 months
Number of injected muscle group(s)
Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.
Time frame: through study completion, an average of 14 months
Injections Practices - Total dose injected per cycle (any indication);
Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.
Time frame: through study completion, an average of 14 months
Time between two injections;
Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.
Time frame: through study completion, an average of 14 months
Criteria for reinjection;
Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.
Time frame: through study completion, an average of 14 months
Reasons for treatment discontinuation, if any, and subsequent therapy if any.
Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.
Time frame: through study completion, an average of 14 months
Change from baseline in Carer Burden Scale (CBS)
Caregiver Burden; The impact of treatment on the physical burden of the caregiver will be assessed by the same caregiver using a modified paper version of the CBS self-administered questionnaire
Time frame: through study completion, an average of 14 months
Change from baseline in ZBI-12 total score to the end of each AboBoNT-A cycle
Treatment Effectiveness; ZBI-12 is a self-administered questionnaire for measuring caregiving burden
Time frame: through study completion, an average of 14 months
Goal score
Treatment Effectiveness; To assess goals achievement it will be used an adapted scale / Therapeutic Goal Attainment Scaling (TGAS) with pre-defined goals
Time frame: through study completion, an average of 14 months
Goal score change
Treatment Effectiveness; To assess goals achievement it will be used an adapted scale / Therapeutic Goal Attainment Scaling (TGAS) with pre-defined goals
Time frame: through study completion, an average of 14 months
Distribution of Goals each AboBoNT-A cycle;
Treatment Effectiveness; To assess goals achievement it will be used an adapted scale / Therapeutic Goal Attainment Scaling (TGAS) with pre-defined goals
Time frame: through study completion, an average of 26 months
Proportion of patients "attaining" the primary Goal
Treatment Effectiveness
Time frame: through study completion, an average of 14 months
Proportion of patients "attaining" at least one Goal
Treatment Effectiveness; To assess goals achievement it will be used an adapted scale / Therapeutic Goal Attainment Scaling (TGAS) with pre-defined goals
Time frame: through study completion, an average of 14 months
Proportion of patients "attaining" the pre-defined goal
Treatment Effectiveness; To assess goals achievement it will be used an adapted scale / Therapeutic Goal Attainment Scaling (TGAS) with pre-defined goals
Time frame: through study completion, an average of 14 months
Change from baseline in Modified Ashworth Scale (MAS) score.
Treatment Effectiveness; Based on routine clinical examination, group muscle tone assessments performed by the Investigator according to the MAS will be recorded
Time frame: through study completion, an average of 14 months
Change from baseline in SQoL-6D total score
Patient's Spasticity-Related Health Status (PS-RHS); The SQoL-6D consists of a 6-dimensions self-administered questionnaire that provides an overall picture of ULS spasticity-related health status
Time frame: through study completion, an average of 14 months
Change from baseline in SQoL-6D pain/discomfort subscore
Patient's Spasticity-Related Health Status (PS-RHS); The SQoL-6D consists of a 6-dimensions self-administered questionnaire that provides an overall picture of ULS spasticity-related health status
Time frame: through study completion, an average of 14 months
Number and percentage of patients with the following concomitant medications: oral antispasticity medications, pain medications (nociceptive and neuropathic pain), psychotropic drugs and anticoagulant drugs.
Concomitant Medications, Non-Drug Therapies and Surgeries
Time frame: Up to 14 months
Number and percentage of patients with the following concomitant non-drug therapies for the management of ULS: physiotherapy and use of orthoses;
Concomitant Medications, Non-Drug Therapies and Surgeries
Time frame: Up to 14 months
Number and percentage of patients with concomitant surgical procedures impacting caregivers' burden and patients' health.
Concomitant Medications, Non-Drug Therapies and Surgeries
Time frame: Up to 14 months
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Feb 2027, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.